Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening

Takashi Kobayashi, Rei Goto, Shiro Hinotsu, Osamu Ogawa

Research output: Contribution to journalArticle

Abstract

In prostate specific antigen (PSA)-based prostate cancer mass screening, the optimal re-screening interval is still in question, although guidelines suggest that a prolonged interval would be safe and cost-saving. We examined the socioeconomic feasibility of prolonged re-screening interval based on individual baseline PSA values. Markov decision-analytic models of prostate cancer screening were established for cost-effectiveness comparison of prolonged re-screening in men with low (≤ 1 ng/ml) PSA level (metainterval strategy) and annual re-screening in every participant (control strategy). Effectiveness and socioeconomic feasibility were evaluated according to quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER; Δ cost per Δ QALY), respectively. As a result, outcomes including cancer detection rates and stage shift suggested that these models well recapitulated actual prostate cancer mass screening. The meta-interval strategy was more cost-effective than the control strategy. The ICER for the control strategy with respect to the meta-interval strategy exceeded US$62,000/QALY through the sensitivity analyses for every assumption. The meta-interval strategy was more effective and less expensive if the trade-off of impaired clinical outcomes caused by delayed detection was small. In conclusion, our models suggest that the meta-interval strategy is more cost-effective than annual screening. It can be even more effective if the interval is determined appropriately such that cancer can be detected within the therapeutic window.

Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalActa Urologica Japonica
Volume59
Issue number3
Publication statusPublished - 2013 Mar
Externally publishedYes

Fingerprint

Mass Screening
Prostate-Specific Antigen
Early Detection of Cancer
Quality-Adjusted Life Years
Prostatic Neoplasms
Costs and Cost Analysis
Cost-Benefit Analysis
Cost Control
Neoplasms
Guidelines
Therapeutics

Keywords

  • PSA-based prostate cancer screening

ASJC Scopus subject areas

  • Urology

Cite this

Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening. / Kobayashi, Takashi; Goto, Rei; Hinotsu, Shiro; Ogawa, Osamu.

In: Acta Urologica Japonica, Vol. 59, No. 3, 03.2013, p. 159-166.

Research output: Contribution to journalArticle

@article{c41cf3d44a68434d89a1164f3aab9187,
title = "Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening",
abstract = "In prostate specific antigen (PSA)-based prostate cancer mass screening, the optimal re-screening interval is still in question, although guidelines suggest that a prolonged interval would be safe and cost-saving. We examined the socioeconomic feasibility of prolonged re-screening interval based on individual baseline PSA values. Markov decision-analytic models of prostate cancer screening were established for cost-effectiveness comparison of prolonged re-screening in men with low (≤ 1 ng/ml) PSA level (metainterval strategy) and annual re-screening in every participant (control strategy). Effectiveness and socioeconomic feasibility were evaluated according to quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER; Δ cost per Δ QALY), respectively. As a result, outcomes including cancer detection rates and stage shift suggested that these models well recapitulated actual prostate cancer mass screening. The meta-interval strategy was more cost-effective than the control strategy. The ICER for the control strategy with respect to the meta-interval strategy exceeded US$62,000/QALY through the sensitivity analyses for every assumption. The meta-interval strategy was more effective and less expensive if the trade-off of impaired clinical outcomes caused by delayed detection was small. In conclusion, our models suggest that the meta-interval strategy is more cost-effective than annual screening. It can be even more effective if the interval is determined appropriately such that cancer can be detected within the therapeutic window.",
keywords = "PSA-based prostate cancer screening",
author = "Takashi Kobayashi and Rei Goto and Shiro Hinotsu and Osamu Ogawa",
year = "2013",
month = "3",
language = "English",
volume = "59",
pages = "159--166",
journal = "Acta Urologica Japonica",
issn = "0018-1994",
publisher = "Editorial Board of Acta Urologica Japonica",
number = "3",

}

TY - JOUR

T1 - Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening

AU - Kobayashi, Takashi

AU - Goto, Rei

AU - Hinotsu, Shiro

AU - Ogawa, Osamu

PY - 2013/3

Y1 - 2013/3

N2 - In prostate specific antigen (PSA)-based prostate cancer mass screening, the optimal re-screening interval is still in question, although guidelines suggest that a prolonged interval would be safe and cost-saving. We examined the socioeconomic feasibility of prolonged re-screening interval based on individual baseline PSA values. Markov decision-analytic models of prostate cancer screening were established for cost-effectiveness comparison of prolonged re-screening in men with low (≤ 1 ng/ml) PSA level (metainterval strategy) and annual re-screening in every participant (control strategy). Effectiveness and socioeconomic feasibility were evaluated according to quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER; Δ cost per Δ QALY), respectively. As a result, outcomes including cancer detection rates and stage shift suggested that these models well recapitulated actual prostate cancer mass screening. The meta-interval strategy was more cost-effective than the control strategy. The ICER for the control strategy with respect to the meta-interval strategy exceeded US$62,000/QALY through the sensitivity analyses for every assumption. The meta-interval strategy was more effective and less expensive if the trade-off of impaired clinical outcomes caused by delayed detection was small. In conclusion, our models suggest that the meta-interval strategy is more cost-effective than annual screening. It can be even more effective if the interval is determined appropriately such that cancer can be detected within the therapeutic window.

AB - In prostate specific antigen (PSA)-based prostate cancer mass screening, the optimal re-screening interval is still in question, although guidelines suggest that a prolonged interval would be safe and cost-saving. We examined the socioeconomic feasibility of prolonged re-screening interval based on individual baseline PSA values. Markov decision-analytic models of prostate cancer screening were established for cost-effectiveness comparison of prolonged re-screening in men with low (≤ 1 ng/ml) PSA level (metainterval strategy) and annual re-screening in every participant (control strategy). Effectiveness and socioeconomic feasibility were evaluated according to quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER; Δ cost per Δ QALY), respectively. As a result, outcomes including cancer detection rates and stage shift suggested that these models well recapitulated actual prostate cancer mass screening. The meta-interval strategy was more cost-effective than the control strategy. The ICER for the control strategy with respect to the meta-interval strategy exceeded US$62,000/QALY through the sensitivity analyses for every assumption. The meta-interval strategy was more effective and less expensive if the trade-off of impaired clinical outcomes caused by delayed detection was small. In conclusion, our models suggest that the meta-interval strategy is more cost-effective than annual screening. It can be even more effective if the interval is determined appropriately such that cancer can be detected within the therapeutic window.

KW - PSA-based prostate cancer screening

UR - http://www.scopus.com/inward/record.url?scp=84876379219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876379219&partnerID=8YFLogxK

M3 - Article

C2 - 23633630

AN - SCOPUS:84876379219

VL - 59

SP - 159

EP - 166

JO - Acta Urologica Japonica

JF - Acta Urologica Japonica

SN - 0018-1994

IS - 3

ER -